With respect to clinical trial activities, the company said recent highlights included:
-- At TCT, Volcano announced sponsorship of the first major study designed
to examine the role of IVUS in accurate stent placement and reduction
of clinical events. This sub-study is part of the ADAPT-DES study being
administered by the Cardiology Research Foundation, which will explore
outcomes for patients with coronary artery disease treated with
drug-eluting stents (DES). IVUS will be used in a 3,000 patient
sub-study to explore the potential benefits of IVUS-guided PCI to
reduce clinical events.
-- Also at TCT, Drs. Gregg Stone and Marty Leon provided data
demonstrating that IVUS can reduce thrombosis risk with DES and
restonsis and thrombosis risk with bare metal stents. In addition, Dr.
Renu Virmani provided data indicating that IVUS can address many of the
procedural, device and lesion factors contributing to late stent
-- Baseline data on 700 PROSPECT trial patients was presented at TCT. Key
findings demonstrated the value of IVUS in the characterization of
major coronary arteries and that IVUS found at least one thin cap
fibroatheroma (TCFA) in 28 percent of patients.
For the first nine months of fiscal 2007, revenues were $90.6 million,
a 23 percent increase over revenues of $73.5 million in the same period a
year ago. On a GAAP basis, the company reported a net loss of $2.8 million,
or $0.07 per share, versus a loss of $10.0 million, or $0.60 per share, in
the same period a year ago. Included in the results for 2006 is a write-off
of $1.2 million, or $0.07 per share, related to deferred debt issuance
costs as a result of the company's initial public offering. Excludi
|SOURCE Volcano Corporation|
Copyright©2007 PR Newswire.
All rights reserved